




RealRate

PHARMACEUTICAL 2021

Citius Pharmaceuticals Inc.
Rank 201 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2021

Citius Pharmaceuticals Inc. Rank 201 of 409

The relative strengths and weaknesses of Citius Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Citius Pharmaceuticals Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 168% points. The greatest weakness of Citius Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 82% points.

The company's Economic Capital Ratio, given in the ranking table, is -127%, being 228% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	13,982
Cost of Goods Sold	0
Intangible Assets	9,347
Liabilities, Current	4,097
Liabilities, Non-Current	855
Other Assets	20,443
Other Compr. Net Income	0
Other Expenses	803
Other Liabilities	5,150
Other Net Income	163
Property and Equipment	1.6
Research and Development	8,813
Revenues	0
Selling, General and Administrative Expense	8,095

Output Variable	Value in 1000 USD
Assets	43,774
Liabilities	10,103
Expenses	17,711
Stockholders Equity	33,671
Net Income	-17,548
Comprehensive Net Income	-17,548
Economic Capital Ratio	-127%

